Literature DB >> 4017676

Experience with surgery for thymoma associated with pure red blood cell aplasia. Report of three cases.

S Fujimura, T Kondo, A Yamauchi, M Handa, T Nakada.   

Abstract

We present three cases of thymoma associated with pure red blood cell aplasia in which thymomectomy and thymectomy were performed. Case 1, a patient with pure red blood cell aplasia and hypogammaglobulinemia, was treated after surgery with immunosuppressive agents. She did not show any remission and died eight months after the operation. Case 2, a patient with pure red blood cell aplasia alone, showed transient erythropoiesis only in the early post-operative period and died one year and seven months after the operation. Patient 3 had pure red blood cell aplasia alone before surgery and was treated after surgery with prednisolone and fluoxymesterone. He showed good remission from the aplasia after these treatments; however, myasthenia gravis appeared seven months after the operation. These results seem to show that such combined therapy as applied in case 3 may be effective for some of the patients with pure red blood cell aplasia and thymoma; however, the effects of thymomectomy or thymectomy (or both) are still controversial for the treatment of pure red blood cell aplasia.

Entities:  

Mesh:

Year:  1985        PMID: 4017676     DOI: 10.1378/chest.88.2.221

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  2 in total

Review 1.  Thymoma associated with pure red cell aplasia: a case report and literature review.

Authors:  Reenus Demel Xavier; Sujith Devaraj; Vijay Sadasivam; Om Prakasam; Narendra Menon; Ashok Hariharan; Thiagarajamurthy Sundaramoorthi
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-03-04

Review 2.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.